| Item type: | Article | ||||
|---|---|---|---|---|---|
| Journal or Publication Title: | Current Cancer Drug Targets | ||||
| Publisher: | BENTHAM SCIENCE PUBL LTD | ||||
| Place of Publication: | SHARJAH | ||||
| Volume: | 5 | ||||
| Number of Issue or Book Chapter: | 6 | ||||
| Page Range: | pp. 393-419 | ||||
| Date: | 2005 | ||||
| Institutions: | Medicine > Lehrstuhl für Dermatologie und Venerologie Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||
| Identification Number: |
| ||||
| Keywords: | ACTIVATED-RECEPTOR-GAMMA; ENDOTHELIAL GROWTH-FACTOR; SELECTIVE CYCLOOXYGENASE-2 INHIBITOR; CELL-CYCLE ARREST; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HUMAN PROSTATE-CANCER; HUMAN HEPATOCELLULAR-CARCINOMA; HUMAN PANCREATIC-CANCER; METASTATIC BREAST-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; tumor-stroma interaction; stroma-targeted therapy; PPAR gamma; COX-2; mTOR; rapamycin; metronomic chemotherapy; tumor angiogenesis; antiangiogenic | ||||
| Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||
| Status: | Published | ||||
| Refereed: | Yes, this version has been refereed | ||||
| Created at the University of Regensburg: | Yes | ||||
| Item ID: | 70487 |
Web of ScienceAbstract
In search of new strategies for the treatment of cancer, the interaction between tumor and stroma attracts more and more attention. Disruption of stroma functions, e.g. angiogenesis, has evolved into a promising target for cancer therapies. Since stromal cells are genetically stable, stroma-targeted therapies seem to be less susceptible to the development of drug resistance. Several ...
Abstract
In search of new strategies for the treatment of cancer, the interaction between tumor and stroma attracts more and more attention. Disruption of stroma functions, e.g. angiogenesis, has evolved into a promising target for cancer therapies. Since stromal cells are genetically stable, stroma-targeted therapies seem to be less susceptible to the development of drug resistance. Several well-established drugs, which had initially been developed for other indications, also exhibit antitumor activity. Among those, PPAR gamma agonists, COX-2 inhibitors, and mTOR antagonists are the most remarkable examples. Current research data and clinical experience suggest that these drugs target stroma functions in cancer, in particular angiogenesis, but immunological mechanisms and direct antitumor effects seem to participate as well. In addition to these drugs, frequent administration of low-dose chemotherapeutics, referred to as metronomic chemotherapy, reveals profound anti-angiogenic effects. In the meantime, a multitude of preclinical and clinical studies have been undertaken, which demonstrate the efficacy of these drugs in cancer therapy. Combinatorial use of these agents has been suggested to be superior in terms of antitumor efficacy and prevention of drug resistance. The toxicity of these therapies is surprisingly low compared with conventional high-dose chemotherapy regimens. Patients with advanced disease, often heavily pretreated and presenting multiple drug resistance, could particularly profit from such tumor-stroma-targeted therapies. However, larger randomized clinical trials are required for further evaluation and optimization of this concept.
Metadata last modified: 19 Dec 2024 14:58
Altmetric